WO2022221886A1 - Compositions for the treatment of benign prostatic hypertrophy - Google Patents
Compositions for the treatment of benign prostatic hypertrophy Download PDFInfo
- Publication number
- WO2022221886A1 WO2022221886A1 PCT/US2022/071781 US2022071781W WO2022221886A1 WO 2022221886 A1 WO2022221886 A1 WO 2022221886A1 US 2022071781 W US2022071781 W US 2022071781W WO 2022221886 A1 WO2022221886 A1 WO 2022221886A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- effective amount
- flavonoid
- fisetin
- omega
- various embodiments
- Prior art date
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 50
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title description 66
- 239000005495 thyroid hormone Substances 0.000 claims abstract description 64
- 229940036555 thyroid hormone Drugs 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 63
- 229940124302 mTOR inhibitor Drugs 0.000 claims abstract description 27
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims description 74
- 229930003935 flavonoid Natural products 0.000 claims description 71
- 150000002215 flavonoids Chemical class 0.000 claims description 71
- 235000017173 flavonoids Nutrition 0.000 claims description 71
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 41
- 235000011990 fisetin Nutrition 0.000 claims description 37
- 229940123208 Biguanide Drugs 0.000 claims description 28
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 28
- 239000003472 antidiabetic agent Substances 0.000 claims description 28
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 28
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 27
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 26
- 229960002930 sirolimus Drugs 0.000 claims description 26
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 22
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical group CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 17
- 229960002600 icosapent ethyl Drugs 0.000 claims description 17
- 229940035722 triiodothyronine Drugs 0.000 claims description 16
- 229960003105 metformin Drugs 0.000 claims description 14
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 14
- 150000002204 fisetin derivatives Chemical class 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 19
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 19
- 210000003932 urinary bladder Anatomy 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000002307 prostate Anatomy 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- -1 mTORCl Proteins 0.000 description 11
- 230000003442 weekly effect Effects 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 8
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 8
- 229940012843 omega-3 fatty acid Drugs 0.000 description 8
- 239000006014 omega-3 oil Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009327 senolytic effect Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- 229940041033 macrolides Drugs 0.000 description 6
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 6
- 229940033080 omega-6 fatty acid Drugs 0.000 description 6
- 208000019206 urinary tract infection Diseases 0.000 description 6
- 229920000926 Galactomannan Polymers 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000005754 cellular signaling Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000002324 minimally invasive surgery Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 4
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 description 4
- 108010085220 Multiprotein Complexes Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 201000003146 cystitis Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 102000034285 signal transducing proteins Human genes 0.000 description 4
- 108091006024 signal transducing proteins Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- 102100029816 DEP domain-containing mTOR-interacting protein Human genes 0.000 description 3
- 208000001089 Multiple system atrophy Diseases 0.000 description 3
- 206010031127 Orthostatic hypotension Diseases 0.000 description 3
- 101710115678 Target of rapamycin complex subunit LST8 Proteins 0.000 description 3
- 102100027802 Target of rapamycin complex subunit LST8 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 239000002160 alpha blocker Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 201000000079 gynecomastia Diseases 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 206010029446 nocturia Diseases 0.000 description 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 241000736355 Euthyroides Species 0.000 description 2
- 101000865183 Homo sapiens DEP domain-containing mTOR-interacting protein Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 description 2
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 description 2
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 2
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 2
- 206010038967 Retrograde ejaculation Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 2
- 208000012931 Urologic disease Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000004800 psychological effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 101710199965 DEP domain-containing mTOR-interacting protein Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 101000690272 Mus musculus Proline-rich AKT1 substrate 1 Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 description 1
- 101710129981 Pituitary-specific positive transcription factor 1 Proteins 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100034733 Proline-rich protein 5 Human genes 0.000 description 1
- 101710124303 Proline-rich protein 5 Proteins 0.000 description 1
- 102100034734 Proline-rich protein 5-like Human genes 0.000 description 1
- 101710132895 Proline-rich protein 5-like Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000024155 regulation of cell adhesion Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940125381 senolytic agent Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Definitions
- the field of the disclosure relates generally to compositions for the treatment of benign prostatic hypertrophy (also referred to as benign prostatic hyperplasia, BPH). More specifically, the field of disclosure relates generally to compositions for the treatment of BPH that include mammalian target of rapamycin (mTOR) inhibitors optionally combined with thyroid hormones.
- BPH benign prostatic hyperplasia
- mTOR mammalian target of rapamycin
- Benign prostatic hypertrophy a benign overgrowth of prostate tissue, is generally a disease that affects men as they age and can cause affected men to experience urinary symptoms including impeded flow of urine and/or semen, frequent and/or urgent need to urinate, nocturia, inability to urinate, and incomplete voiding of the bladder.
- the disease can be a significant factor in the development of bladder, urinary tract and kidney diseases.
- the urethra which carries urine from the bladder, passes from the bladder and directly through the prostate gland. When the prostate gland becomes enlarged, it applies pressure on the urethra and/or the bladder, which can impede the flow of urine and/or semen either partially or completely.
- BPH aging, family history, diabetes, heart diseases, erectile dysfunction and obesity.
- BPH is rarely diagnosed in men prior to the age of 40, but the risk of onset increases from the age of 40 on and may be as high as 90% in men that are 80 years of age or older.
- severe cases of BPH there is a complete blockage of urine flow that may require surgical intervention or catheter insertion to drain the bladder. Incomplete voiding of the bladder as a result of BPH increases the risk of developing urinary tract infections; bladder stones that can cause bladder infection, irritation and hematuria; and damage to the muscular wall of the bladder.
- the kidneys may also be damaged by the inability to effectively urinate or from bladder or urinary tract infections that reach the kidneys.
- BPH is not considered a precursor to prostate cancer, nor is it believed to increase the risk of developing prostate cancer.
- treatments for BPH including surgery, medications, and minimally invasive procedures to reduce the size of the prostate, some of these treatments may be contraindicated depending on the severity of the disease, other health conditions and side effects associated with the treatments.
- Medications that are commonly used to treat BPH include 5-alpha reductase inhibitors, alpha-adrenergic blockers, phosphodiesterase-5 inhibitors or combinations thereof; however, symptom improvement is experienced by only about 30-60% of men and it is not currently possible to predict which patients will benefit from these therapies.
- Some of these therapies are required to be continued indefinitely and can have adverse effects including sexual dysfunction, physical changes including gynecomastia, muscle weakness and orthostatic hypotension, and psychological effects including depression, anxiety, and suicidal thoughts. New treatment approaches are needed.
- compositions for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
- compositions for the treatment of benign prostatic hypertrophy comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
- Approximating language may be applied to modify any quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term or terms, such as “about,” “approximately,” and “substantially,” are not to be limited to the precise value specified. In at least some instances, the approximating language may correspond to the precision of an instrument for measuring the value.
- range limitations may be combined and/or interchanged; such ranges are identified and include all the sub-ranges contained therein unless context or language indicates otherwise.
- the term "patient” refers to a warm-blooded animal such as a mammal which is the subject of a medical treatment for a medical condition that causes at least one symptom. It is understood that at least humans, dogs, cats, and horses are within the scope of the meaning of the term. In some aspects, the patient is human. Generally, as used herein, the term “patient” means a human or an animal for which the compositions of the disclosure may be administered.
- the terms “treat”, “treating”, and “treatment” include inhibiting the pathological condition, disorder, or disease, e.g., arresting or reducing the development of the pathological condition, disorder, or disease or its clinical symptoms; or relieving the pathological condition, disorder, or disease, e.g., causing regression of the pathological condition, disorder, or disease or its clinical symptoms. These terms encompass also therapy and cure. Treatment means any manner in which the symptoms of a pathological condition, disorder, or disease are ameliorated or otherwise beneficially altered.
- BPH benign prostatic hypertrophy
- BPH prostatic hyperplasia benign prostatic hyperplasia
- mTOR complex 1 refers to a protein complex comprising mTOR, regulatory-associated protein of mTOR (RAPTOR), mammalian lethal with SEC 13 protein 8 (mLST8), proline-rich AKT substrate of 40 kDa (PRAS40) and DEP domain-containing protein 6 (DEPTOR) that has been described to function as a nutrient/energy/redox sensor; regulator of cellular growth, proliferation, and motility; and controller of protein synthesis with roles in inflammation, autophagy and cell survival.
- RAPTOR regulatory-associated protein of mTOR
- mLST8 mammalian lethal with SEC 13 protein 8
- PRAS40 proline-rich AKT substrate of 40 kDa
- DEPTOR DEP domain-containing protein 6
- mTOR complex 2 refers to a protein complex comprising mTOR, mLST8, DEPTOR, rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-activated protein kinase interacting protein 1 (mSINl), and protein observed with rictor 1 and 2 (PROTORI/2) that has been described to function as an activator of insulin receptors and insulin-like growth hormone factor 1 receptors; and regulator of cell proliferation, cell migration and cytoskeletal remodeling with roles in signaling the production of cytokines, inflammation and cell survival.
- RICTOR rapamycin-insensitive companion of mTOR
- mSINl mammalian stress-activated protein kinase interacting protein 1
- PROTORI/2 protein observed with rictor 1 and 2
- mTOR inhibitor refers to a composition that either directly or indirectly inhibits one or more functions of mTOR, mTORCl, mTORC2 and combinations thereof.
- suitable mTOR inhibitors include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit one or more mTOR protein complex functions.
- thyroid hormone refers to a composition that is either equivalent to, a derivative of, or affects the same functions as triiodothyronine (T3).
- suitable thyroid hormones include liothyronine, a T3 thyroid hormone composition.
- BPH pathology of BPH involves a benign overgrowth of the prostate tissue to an extent that the prostate applies pressure to the urethra and/or the bladder and may cause one or more associated symptoms including impeded flow of urine, frequent and/or urgent need to urinate, nocturia, inability to urinate, and incomplete voiding of the bladder.
- the development of BPH is believed to be generally related to age with increased risk of experiencing the disease and its symptoms associated with family history, diabetes, heart diseases, erectile dysfunction and obesity. BPH can be a significant factor in the development of bladder, urinary tract and kidney diseases.
- BPH is believed to be most common in men that are 80 years of age or older (about 50-90% or more), and less common at younger ages (about 33-50% by age 60 and relatively rare below age 40). In some cases, genetic factors have been shown to increase the risk of developing BPH up to six-fold. In severe cases of BPH, there is a complete blockage of urine flow that may require surgical intervention or catheter insertion to drain the bladder. In most cases of BPH, incomplete voiding of the bladder is believed to result in increased risk of developing urinary tract infections; bladder stones; bladder infections, bladder irritation, hematuria; and damage to the muscular wall of the bladder. The kidneys may also be damaged by the inability to effectively urinate or from bladder or urinary tract infections that reach the kidneys. However, BPH is not believed to be a precursor to prostate cancer, nor is it believed to increase the risk of developing prostate cancer.
- BPH While several different treatments for BPH are available, including surgery, medications, and minimally invasive procedures to reduce the size of the prostate, some of these treatments may be contraindicated depending on the severity of the disease, other health conditions and side effects associated with the treatments. Mild cases of BPH may only call for active surveillance with recommendations for specific changes in diet and exercise. Whereas, moderate to severe cases of BPH generally involve treatment of some kind. Many options are currently available for treatment of BPH that have varying levels of success and potential side effects.
- Medications are often prescribed to treat BPH prior to considering surgical options.
- Some of the pharmaceutical options include 5-alpha reductase inhibitors, alpha-adrenergic blockers, phosphodiesterase-5 inhibitors, or any combination thereof.
- Certain phytotherapies herebal supplements, e.g. saw palmeho
- saw palmeho have also been touted for their ability to treat BPH, but these therapies are not generally recommended by doctors and have been proven to be ineffective in several studies.
- 5-alpha reductase inhibitors have proven to have some beneficial effect in only about two-thirds of patients and are believed to act by blocking the production of the male hormone, dihydrotestosterone (DHT), which has been associated with activating prostate cell growth.
- DHT dihydrotestosterone
- 5-alpha reductase inhibitors are required to be continued indefinitely and the side effects can include impotence and gynecomastia as well as other sexual, physical, and psychological symptoms that may persist even after discontinuing therapy.
- Alpha-adrenergic blockers which are believed to act by relaxing smooth muscle tissue in blood vessels and the prostate, have also proven to benefit only about two-thirds of patients with BPH. These agents also have side effects including orthostatic hypotension, fatigue, headaches, and ejaculatory dysfunction.
- Phosphodiesterase-5 inhibitors are also believed to act by relaxing smooth muscle of the prostate and bladder; however, despite exhibiting some beneficial effects of reducing urinary frequency and urgency, urinary flow was not shown to be significantly improved.
- adverse effects can include sexual dysfunction, physical changes including gynecomastia, muscle weakness and orthostatic hypotension, and psychological effects including depression, anxiety, and suicidal thoughts.
- Minimally invasive procedures are often used after medicinal treatment has failed to be effective, and more invasive surgeries are considered when other methods have failed, or in the more severe cases of BPH.
- Minimally invasive procedures are not believed to reduce the risk that the patient will require subsequent surgery or additional medication, and these procedures may have side effects including hematuria, burning sensation when urinating, need to urinate more frequently, urinary tract infections, retrograde ejaculation, and erectile dysfunction.
- Examples of minimally invasive procedures include prostatic urethral lift, water vapor thermal therapy, transurethral microwave therapy, and catheterization.
- More invasive surgery in more severe cases of BPH include transurethral incision of the prostate, photoselective vaporization, transurethral resection of the prostate, holmium laser enucleation of prostate, thulium laser enucleation of the prostate, transurethral vaporization of the prostate and transurethral water-jet ablation.
- Possible side effects of more invasive therapies include urinary tract infections, urinary incontinence, dry orgasm, retrograde ejaculation, and erectile dysfunction.
- omega-6 fatty acids stimulate the growth of prostatic cells
- omega-3 fatty acids provide an inhibitory effect on prostate cell growth.
- Some of the changes believed to occur involve an increase in omega- 6 to omega-3 fatty acids that can interfere with the normal presentation and function of certain membrane-bound receptors including cell bound enzymes, calcium channels, sodium channels, potassium channels and other signaling proteins.
- the membrane bound proteins can become less responsive to stimuli including hormones, cell signaling proteins and cell signaling substances, which may in part be due to oxidative stress over time leading to changes in mTOR complex gene regulation and degradation of the omega-3 to omega-6 fatty acid ratio in cellular membranes.
- inflammation and improper immune response is associated with and can be contributing factors for predisposition to the development of BPH. It is believed that an inflammatory environment is created that is promoted by inflammatory cytokines and other chemicals, some of which are released from cell membranes as a result of an imbalance of the ratio of omega-3 to omega-6 fatty acids and some of which are released from senescent cells that accumulate over time associated with aging. It is also believed that these pro-tumorigenic immune responses and inflammation are factors in inducing the growth of the prostate tissue.
- mTORCl and mTORC2 control multiple diffuse aspects of cellular metabolism, cellular integrity, cellular death, immune response and inflammation. It is believed that the mTORCl and mTORC2 activity is enhanced and driven upwards by cytokine release including those released as a result of higher than optimal ratios of omega-6 to omega-3 fatty acids in the cell membrane and that mTORCl and mTORC2 complex functions may be down regulated by the use of mTOR inhibitors.
- suitable mTOR inhibitors may include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit mTOR protein complexes.
- omega-3 fatty acids include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are generally derived from diet. It is believed that EPA is superior to DHA for inhibition of inflammation and maintaining cell integrity. It is believed that omega-6 fatty acids (e.g. arachidonic acids) are precursors to the formation of cytokines.
- omega-3 fatty acids may help to decrease cytokine production, for example, from the action of eicosanoid molecules. Accordingly, a decrease of omega-3 fatty acids, in relation to omega-6, may facilitate an inflammatory response caused by cytokines.
- therapies including omega-3 fatty acids may downshift cellular signaling by decreasing cytokine formation. This may increase the maintenance of cellular adhesion and normal membrane anatomy with better sodium, potassium and calcium channel function and better response to stimuli from hormones, cell signaling proteins and other cell signaling substances such as nitric oxide. Therapies including omega-3 fatty acids may also facilitate the maintenance of membranes of mitochondria and other intracellular structures.
- mTOR-associated protein complexes may also be of importance in the treatment of BPH. It is believed that mTOR-associated protein complexes may respond to stimuli that alter cellular metabolism and growth. The mTOR- associated protein complexes may be involved in many diseases and almost all tissues of the body, including the prostate. It is believed that the dysregulation of mTORCl and mTORC2 may be an underlying cause of disease over one’s lifetime. It is also believed that overactivity of these protein complexes may lead to BPH.
- biguanide antihyperglycemic agents act through inhibition of the mTORC2 complex to modulate cell functions including metabolism, proliferation, migration, and survival as well as reduce oxidative stress and inflammation. It is further believed that biguanide antihyperglycemic agents inhibit the mTORC2 complex by mechanisms including the reduction of the downstream effects of the AKT protein that is a component of the PBK/AKT/mTOR pathway.
- the PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle and is necessary to promote growth and proliferation over differentiation of adult stem cells. However, in BPH, this pathway is overactive, thus reducing apoptosis and allowing cell hypertrophy and proliferation. It is further believed that biguanide antihyperglycemic agents may be effective in treating BPH by reducing the downstream effect of the AKT protein in the PBK/AKT/mTOR pathway.
- flavonoids act as senolytic agents by reducing mTOR complex activity, increasing the activity of sirtuins, and increasing the activity of AMP-activated protein kinase (AMPK). These actions are believed to play a role in cellular energy homeostasis and promotion of apoptosis in senescent cells that are resistant to signaling proteins and accumulate as we age during the aging process. It is further believed that the accumulation of senescent cells results from a weakened immune system related to aging, and these cells provide a source of chronic inflammation through the release of inflammatory chemicals and may lead to an increased risk of BPH.
- AMPK AMP-activated protein kinase
- certain flavonoids used in combination with a biguanide antihyperglycemic agent can exhibit synergistic effects for promoting apoptosis in senescent cells while promoting homeostasis in normal cells. It is further believed that when certain flavonoids are combined with certain galactomannans, the absorption of the certain flavonoids can be increased by as much as 25-fold.
- compositions that include one or more mTOR inhibitors may be effective at treating BPH by decreasing inflammation, enhancing cell membrane stability and function, and promoting apoptosis in senescent cells. It is also believed that compositions comprised of one or more mTOR inhibitors may be more effective if the composition is comprised of at least two or more mTOR inhibitors.
- Thyroid hormones including e.g. liothyronine (a T3 thyroid hormone), are believed to assist in controlling metabolism by utilizing oxygen and calories for conversion into energy in the mitochondria through the formation of ATP. Thyroid hormones are believed to be necessary for energy production in all organs, especially in muscle, brain, heart, and other tissues. Increased levels of thyroid hormones are believed to affect increased levels of cellular metabolism. Various tests are available to determine thyroid hormone levels, e.g. by measuring the amount of thyroid hormone levels in the blood. Thyroid hormones are believed to enhance cell survival and the metabolism of fats, proteins, and carbohydrates. It is further believed that treatment comprising one or more thyroid hormones in combination with a flavonoid, such as fisetin may act synergistically to increase metabolism and promote the senolytic effects of fisetin.
- a flavonoid such as fisetin
- Thyroid hormones are believed to affect nearly every cell of the body through receptors in the nucleus of the cell. Thyroid hormones bind to DNA-binding nuclear hormone receptors, cause conformational changes in the receptors, and activate transcription of the thyroid hormone sensitive genes by either initiating expression or upregulation. Also, functions of the PI3K/AKT pathway are believed to include regulation of cell adhesion, cell cycle progression, cell survival and signaling. Precursors to the thyroid hormones, referred to as T4 or thyroxine, are believed to stimulate the PI3/AKT pathway in the cytoplasm, whereas T3 does not. T3 also has a shorter half-life than T4, so T3 is recommended for the treatment of hepatic steatosis over T4.
- rapamycin is primarily an mTORl inhibitor at lower doses and for short treatment cycles, whereas high levels and very prolonged treatment cycles can also inhibit mTOR2 by blocking mTOR2 production by the cell.
- Rapamycin treatment is normally administered continuously either orally or intravenously, which frequently causes side effects of insulin resistance and hyperglycemia, and causes immune deficiency. Also, long-term treatment with rapamycin may decrease antigen processing and inhibit T-cell proliferation leading to suppression of the immune system. Rapamycin is also believed to decrease the phosphorylation of the ribosomal s6 kinase, S6K1, which is believed to result in active decreases in protein synthesis and cell mortality.
- rapamycin could be effective and safe if rapamycin is dosed at low-levels either intermittently or in conjunction with other mTOR inhibitors and/or additional medications that decrease or down regulate the PI3K-AKT pathway. It is further believed that using a biguanide antihyperglycemic agent, such as metformin, in these treatment regimens will allow for down regulation of both mTORl and mTOR2 safely without causing significant side effects of high-dose rapamycin. In addition to acting as an inhibitor of mTOR2, metformin also decreases glycolysis and is effective in controlling blood glucose levels.
- a flavonoid such as fisetin
- the addition of a flavonoid is believed to provide the added benefit of promoting apoptosis or cell death of senolytic cells effectuated at least partly through its inhibition of the mTOR pathway.
- the effects of fisetin may be further improved with the addition of a T3 thyroid hormone. It is believed that synergy of activity for inhibition of the PI3K-AKT pathway can be achieved with the combination of rapamycin, metformin, and fisetin while providing a low risk of side effects.
- the treatment regimens could further benefit from the addition of an omega-3 fatty acid derivative, which is believed to downregulate mTOR2, decrease cytokine formation, strengthen cell membranes and structures, and decrease phosphorylation of phosphatides. Additionally, the addition of a T3 thyroid hormone is believed to enhance the effectiveness of the therapy regimen.
- These combination therapies are believed to have minimal side effects, may be administered continuously over long periods of time, and result in an effective decrease in PI3K-
- the composition of the disclosure includes a composition for the treatment of BPH that includes an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
- suitable mTOR inhibitors may include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit mTOR protein complexes.
- suitable thyroid hormones may include a T3 hormone, such as liothyronine.
- At least one of the components of the composition will decrease pro- tumorigenic inflammation associated with cancer and primary cancer treatments.
- At least one of the components of the composition will decrease the rate of normal cell death or will increase the life span of normal cells including those involved in immune response systems.
- at least one of the components of the composition will enhance cellular membrane integrity and function and/or induce apoptosis in cancer and/or senescent cells.
- the compositions of the disclosure include a flavonoid, such as fisetin, at doses that are high enough to cause senescent cells to die and results in an overall decrease in inflammation in the patient.
- compositions of the disclosure include at least an effective amount of a biguanide antihyperglycemic agent in combination with an effective amount of an omega- 3 fatty acid derivative.
- compositions of the disclosure include a thyroid hormone concurrent with high doses of a flavonoid, such as fisetin.
- the composition may include an effective amount of an omega-3 fatty acid derivative.
- Suitable omega-3 fatty acid derivatives may include icosapent ethyl.
- the composition of the disclosure may include an effective amount of at least about 0.5 g of icosapent ethyl, or between about 0.5 g to about 10.0 g, or 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
- the amount of icosapent ethyl is sufficient to maintain an optimum level of icosapent ethyl in the blood of a subject receiving an administration of the composition.
- the composition of the disclosure may include an effective amount of a biguanide antihyperglycemic agent. Suitable biguanide antihyperglycemic agents include metformin. In various embodiments, the composition may include an effective amount of at least about 50 mg of biguanide antihyperglycemic agent, or between about 50 mg to about 4000 mg, or 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, 1200, 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 14
- 3950, 3975, or 4000 mg or any range between any two of these amounts including about 250 mg to about 4000 mg, about 250 mg to about 500 mg, about 250 mg to about 750 mg, 250 mg to about 1000 mg, about 250 mg to about 1250 mg, about 250 mg to about 1500 mg, or between about 500 mg to about 3000 mg.
- the composition may include an effective amount of a flavonoid.
- Suitable flavonoid agents include fisetin and fisetin derivatives.
- the composition may include an effective amount of at least about 10 mg/kg of patient body weight of a flavonoid, or between about 10 mg/kg to about 100 mg/kg of patient body weight, or 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg/kg of patient body weight or any range between any two of these amounts including about 10 mg/kg to about 20 mg/kg, about 15 mg/kg to about 25 mg/kg, about 20 mg/kg to about 30 mg/kg, about 25 mg/kg to about 50 mg/kg, or about 20 mg/kg to about 100 mg/kg.
- the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition.
- such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid.
- the composition may include an effective amount of a flavonoid.
- Suitable flavonoid agents include fisetin and fisetin derivatives.
- the composition may include an effective amount at least about 50 mg of a flavonoid, or between about 50 mg to about 750 mg, or 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190,
- the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition.
- such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid.
- the compositions may include an effective amount of a macrolide.
- Suitable macrolides include rapamycin.
- the compositions may include an effective amount of a macrolide of at least about 0.1 mg of a macrolide, or between about 0.1 mg to about 10 mg, or 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2,
- the amount of rapamycin is administered as a loading dose followed by a lower daily dose.
- the amount of rapamycin is sufficient to maintain an optimum level of rapamycin in the blood of a subject receiving an administration of the composition; such optimum level may be determined as a preferred optimum trough level as measured in nanograms per ml of blood.
- the administration of rapamycin is provided intermittently at low levels.
- the compositions may include an effective amount of a thyroid hormone. Suitable thyroid hormones include the T3 liothyronine. In various embodiments, the compositions of the disclosure may include an effective amount of at least about 1 pg of liothyronine, or between about 1 pg to about 250 pg, or 1, 2, 3, 4, 5, 6, 7, 8, 9,
- the amount of liothyronine is sufficient to maintain an optimum level of liothyronine in the blood of a subject receiving an administration of the composition.
- the compositions may include an effective amount of a combination of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones. In various embodiments, the compositions may include an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a flavonoid. In various embodiments, the compositions may include an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a high dose of a flavonoid, which is associated with a senolytic effect.
- the composition of the disclosure may further contain additional pharmaceutically acceptable carriers.
- the pharmaceutical compositions may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulation, solution or suspension, in a form suitable for parenteral injection as a sterile solution, suspension, or in a form of an emulsion for topical administration as an ointment or cream or for rectal administration as a suppository.
- the pharmaceutical compositions may be in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical compositions may include conventional pharmaceutical carriers or excipients.
- the compositions may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- the composition may be administered to a patient through any suitable route of administration effective in delivering an amount of active agent or active agents to a patient. Suitable routes of administration include oral, parenteral, enteral, and rectal or the like.
- the composition will comprise each of the ingredients in a single administration form, such as a pill, tablet, capsule, oral solution, injection solution, infusion solution, or any of the forms described herein.
- the composition will comprise a kit comprising each of the individual ingredients, together with instructions for administering each ingredient.
- certain ingredients will already be combined such that two, three, or more of the components or ingredients of the composition are in a single administration form as described herein.
- Various embodiments of the disclosure further relate to methods for the treatment of BPH comprising the administration of a composition of an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
- suitable mTOR inhibitors may include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit mTOR protein complexes.
- suitable thyroid hormones may include a T3 hormone, such as liothyronine.
- the methods may include administering an effective amount of an omega-3 fatty acid derivative.
- Suitable omega-3 fatty acid derivatives may include icosapent ethyl.
- the methods may include administering an effective amount of at least about 0.5 g of icosapent ethyl, or between about 0.5 g to about 10.0 g, or 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
- the method may include administering an effective amount of a biguanide antihyperglycemic agent.
- Suitable biguanide antihyperglycemic agents include metformin.
- the methods may include administering an effective amount of at least about 50 mg of biguanide antihyperglycemic agent, or between about 50 mg to about 4000 mg, or 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, 1200, 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 1475, 1500, 1525, 1550, 1575, 1600, 1625, 1650, 1675, 1700, 1725, 1750,
- the method may include administering an effective amount of a flavonoid.
- Suitable flavonoid agents include fisetin and fisetin derivatives.
- the methods may include administering an effective amount of at least about 10 mg/kg of patient body weight of a flavonoid, or between about 10 mg/kg to about 100 mg/kg of patient body weight, or 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg/kg of patient body weight or any range between any two of these amounts including about 10 mg/kg to about 20 mg/kg, about 15 mg/kg to about 25 mg/kg, about 20 mg/kg to about 30 mg/kg, about 25 mg/kg to about 50 mg/kg, or about 20 mg/kg to about 100 mg/kg once, twice, or three or more times daily, weekly, monthly, trimonthly or intermittently with periods between administration when no flavonoid is administered.
- the flavonoid may be administered each day for two days on a weekly, monthly or trimonthly basis. In some preferred methods, the flavonoid may be administered each day for two days twice monthly for six months followed by administration one day per month. In some preferred methods, the flavonoid may be administered once every two weeks on a monthly basis for six to twelve months followed by administration once every month. In some preferred methods, the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition; such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid. In various embodiments, a higher dose of fisetin may be associated with a senolytic effect. In various embodiments, a lower dose of fisetin may be associated with an antioxidant effect.
- the method may include administering an effective amount of a flavonoid that is administered on a daily basis.
- Suitable flavonoid agents include fisetin and fisetin derivatives.
- the methods may include administering an effective amount of at least about 50 mg of a flavonoid, or between about 50 mg to about 750 mg, or 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240,
- the flavonoid may be administered each day for two days on a weekly, monthly or trimonthly basis. In some preferred methods, the flavonoid may be administered each day for two days twice monthly for six months followed by administration one day per month. In some preferred methods, the flavonoid may be administered once every two weeks on a monthly basis for six to twelve months followed by administration once every month.
- the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition; such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid.
- a higher dose of fisetin may be associated with a senolytic effect.
- a lower dose of fisetin may be associated with an antioxidant effect.
- the methods may include administering an effective amount of a macrolide.
- Suitable macrolides include rapamycin.
- the methods may include administering an effective amount of a macrolide of at least about 0.1 mg of a macrolide, or between about 0.1 mg to about 10 mg, or 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0,
- the amount of rapamycin is administered as a loading dose followed by a lower daily dose.
- the amount of rapamycin is sufficient to maintain an optimum level of rapamycin in the blood of a subject receiving an administration of the composition; such optimum level may be determined as a preferred optimum trough level as measured in nanograms per ml of blood.
- the administration of rapamycin is provided intermittently at low levels.
- the methods may include administering an effective amount of an omega-3 fatty acid derivative in a dosing regimen with an effective amount of a biguanide antihyperglycemic agent.
- the methods may include administering an effective amount of an omega-3 fatty acid derivative in a dosing regimen with an effective amount of a flavonoid.
- the methods may include administering an effective amount of a biguanide antihyperglycemic agent in a dosing regimen with an effective amount of a flavonoid.
- the methods may include administering an effective amount of an omega-3 fatty acid derivative in a dosing regimen with an effective amount of a biguanide antihyperglycemic agent and an effective amount of a flavonoid.
- the methods may include administering an effective amount of a thyroid hormone.
- Suitable thyroid hormones include the T3 liothyronine.
- the methods of the disclosure may include administering an effective amount of at least about 1 pg of liothyronine, or between about 1 pg to about 250 pg, or 1, 2, 3, 4, 5, 6, 7,
- the amount of liothyronine administered is sufficient to maintain an optimum level of liothyronine in the blood of a subject receiving an administration of the composition.
- the methods may include diagnosing thyroid functions in each patient prior to administration of an effective amount of a thyroid hormone.
- the methods for patients requiring thyroid hormone replacement in order to establish normal thyroid functions may preferentially be administered a T3 thyroid hormone.
- patients with normal thyroid functions may be administered a low dose of a T3 thyroid hormone (e.g. 5 to 10 pg of liothyronine) combined with a high dose of a flavonoid.
- the methods may include administering a combination of a low dose of a T3 thyroid hormone and a high dose of a flavonoid that effectively elicits a synergistic effect of increasing fat metabolism and promoting cellular senescence.
- the methods include administering a thyroid hormone concurrent with high doses of a flavonoid, such as fisetin.
- the methods may include administering an effective amount of a combination of thyroid hormones. Suitable thyroid hormones that may be included in the combination include the T3 liothyronine. In various embodiments, the methods may include administering an effective amount of a combination of one or more thyroid hormones with an effective amount of a flavonoid. In various embodiments, the methods may include administering an effective amount of one or more thyroid hormones and an effective amount of a high dose of a flavonoid, which is associated with a senolytic effect unless the patient is hypo thyroid on the days of the week the thyroid hormone is administered.
- the methods may include administering a combination of an effective amount of one or more thyroid hormones with either an effective amount of a flavonoid or a high dose of a flavonoid, wherein only some of the compositions that include an effective amount of a flavonoid also include an effective amount of one or more thyroid hormones.
- an effective amount of one or more thyroid hormones may be included only in one of two weekly compositions administered that includes an effective amount of a flavonoid or a high dose of a flavonoid, which composition could be either the first or second weekly composition administered that includes a flavonoid or high dose flavonoid.
- the methods may include administering an effective amount of a combination of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones. In various embodiments, the methods may include administering an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a flavonoid. In various embodiments, the methods may include administering an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a high dose of a flavonoid, which is associated with a senolytic effect.
- the methods may include administering a combination of an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and either an effective amount of a flavonoid or a high dose of a flavonoid, wherein only some of the compositions that include an effective amount of a flavonoid also include an effective amount of one or more thyroid hormones.
- an effective amount of one or more thyroid hormones may be included only in one of two weekly compositions administered that includes an effective amount of a flavonoid or a high dose of a flavonoid, which composition could be either the first or second weekly composition administered that includes a flavonoid or high dose flavonoid.
- the one or more thyroid hormones should be administered for short durations (for example, two days a week, bimonthly, or monthly) during any periods of a dosing regimen that include a high dose of a flavonoid.
- the methods include administering a macrolide, such as rapamycin; in combination with a biguanide antihyperglycemic agent, such as metformin; in combination with an omega-3 fatty acid derivative, such as icosapent ethyl; in combination with a flavonoid, such as fisetin; and in combination with a T3 thyroid hormone, such as liothyronine.
- the methods include administering a macrolide, such as rapamycin, dosed weekly to achieve blood levels below specified levels measured at specified times following administration; in combination with a biguanide antihyperglycemic agent, such as metformin, dosed twice daily; in combination with an omega-3 fatty acid derivative, such as icosapent ethyl, dosed twice daily; in combination with a flavonoid, such as fisetin, dosed daily; in combination with a T3 thyroid hormone, such as liothyronine, dosed either for two days in a row per week or dosed on separated days for no more than 3 days per week.
- a macrolide such as rapamycin
- the methods include administering a macrolide, such as rapamycin, dosed weekly to achieve blood levels below about 12 nanograms per ml of blood measured at about 60 hours plus or minus 3 hours following administration; in combination with a biguanide antihyperglycemic agent, such as metformin, dosed twice daily at about 500 mg to about 2000 mg; in combination with an omega-3 fatty acid derivative, such as icosapent ethyl, dosed twice daily at about 2.0 g to about 4.0 g; in combination with a flavonoid, such as fisetin, dosed daily at about 20.0 mg/kg patient body weight (which dose may be achieved by starting at a daily dose of about 200 mg and stepping up to the daily dose of about 20.0 mg/kg); in combination with a T3 thyroid hormone, such as liothyronine, dosed either for two days in a row per week or dosed on separated days for no more than 3 days per week at about 5.0 pg to about 10.0
- the methods include administering a composition that does not include a macrolide, such as rapamycin, when it is not clinically necessary.
- a macrolide such as rapamycin
- the macrolide is administered intermittently, as directed by a physician.
- the macrolide is administered daily or twice daily as set forth above for a period of 1, 2, 3, 4,
- the methods may include administering the effective amount of the compositions of the disclosure that may further contain at least one additional pharmaceutically acceptable carriers, excipients, other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- the methods may include administering the effective amount of the compositions to a patient through any suitable route of administration effective in delivering an amount of active agent or active agents to a patient.
- suitable routes of administration include oral, intravascular, intramuscular, subcutaneous, parenteral, enteral, and rectal or the like.
- the methods may include administering the effective amount of the compositions comprised of each of the ingredient in a single administration form, such as a pill, tablet, capsule, oral solution, injection solution, infusion solution, or any of the forms described herein.
- the methods may include administering the effective amount of the compositions from a kit comprising each of the individual ingredients, together with instructions for administering each ingredient. In some forms of the kit, certain ingredients will already be combined such that one, two, three, four, or more of the components or ingredients of the composition are in a single administration form as described herein.
- Normal total PSA levels are considered to be at or below 4.0 ng/ml.
- a patient experiencing elevated total PSA levels of about 5.3 ng/ml on average during about a 4 year period was treated with the following regimen: Vescepa® (icosapent ethyl) dosed at 2 grams twice daily, metformin dosed twice daily at 750 mg each morning and 500 mg each evening, and fisetin dosed two times weekly at 1,400 mg on Monday and Tuesday of each week.
- the treatment regimen was conducted for 1 month at which time total PSA levels were tested and found to return to a normal level of 3.89 ng/ml, representing about a 27% decrease in total PSA level.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided herein are pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further provided herein are methods for administering pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
Description
COMPOSITIONS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
FIELD
[0001] The field of the disclosure relates generally to compositions for the treatment of benign prostatic hypertrophy (also referred to as benign prostatic hyperplasia, BPH). More specifically, the field of disclosure relates generally to compositions for the treatment of BPH that include mammalian target of rapamycin (mTOR) inhibitors optionally combined with thyroid hormones.
BACKGROUND
[0002] Benign prostatic hypertrophy, a benign overgrowth of prostate tissue, is generally a disease that affects men as they age and can cause affected men to experience urinary symptoms including impeded flow of urine and/or semen, frequent and/or urgent need to urinate, nocturia, inability to urinate, and incomplete voiding of the bladder. The disease can be a significant factor in the development of bladder, urinary tract and kidney diseases. The urethra, which carries urine from the bladder, passes from the bladder and directly through the prostate gland. When the prostate gland becomes enlarged, it applies pressure on the urethra and/or the bladder, which can impede the flow of urine and/or semen either partially or completely.
[0003] Certain factors, if present, can increase the risk of developing BPH including aging, family history, diabetes, heart diseases, erectile dysfunction and obesity. BPH is rarely diagnosed in men prior to the age of 40, but the risk of onset increases from the age of 40 on and may be as high as 90% in men that are 80 years of age or older. In severe cases of BPH, there is a complete blockage of urine flow that may require surgical intervention or catheter insertion to drain the bladder. Incomplete voiding of the bladder as a result of BPH increases the risk of developing urinary tract infections; bladder stones that can cause bladder infection, irritation and hematuria; and damage to the muscular wall of the bladder. The kidneys may also be damaged by the inability to effectively urinate or from bladder or urinary tract infections that reach the kidneys. However, BPH is not considered a precursor to prostate cancer, nor is it believed to increase the risk of developing prostate cancer.
[0004] While several different treatments for BPH are available, including surgery, medications, and minimally invasive procedures to reduce the size of the prostate, some of these treatments may be contraindicated depending on the severity of the disease, other health conditions and side effects associated with the treatments. Medications that are commonly used to treat BPH include 5-alpha reductase inhibitors, alpha-adrenergic blockers, phosphodiesterase-5 inhibitors or combinations thereof; however, symptom improvement is experienced by only about 30-60% of men and it is not currently possible to predict which patients will benefit from these therapies. Some of these therapies are required to be continued indefinitely and can have adverse effects including sexual dysfunction, physical changes including gynecomastia, muscle weakness and orthostatic hypotension, and psychological effects including depression, anxiety, and suicidal thoughts. New treatment approaches are needed.
BRIEF DESCRIPTION
[0005] Disclosed herein are pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
[0006] In other aspects, disclosed herein are methods for administering pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.
DETAILED DESCRIPTION
[0007] In the following specification and the claims, reference will be made to a number of terms, which shall be defined to have the following meanings. The singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. The terms “comprising,” “including,” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements. “Optional” or “optionally” means that the subsequently described event or a circumstance may or may not occur, and that the description includes instances where the event occurs and instances where it does not.
[0008] Approximating language, as used herein throughout the specification and claims, may be applied to modify any quantitative representation that could permissibly vary without
resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term or terms, such as “about,” “approximately,” and “substantially,” are not to be limited to the precise value specified. In at least some instances, the approximating language may correspond to the precision of an instrument for measuring the value. Here and throughout the specification and claims, range limitations may be combined and/or interchanged; such ranges are identified and include all the sub-ranges contained therein unless context or language indicates otherwise.
[0009] As used herein, the term "patient" refers to a warm-blooded animal such as a mammal which is the subject of a medical treatment for a medical condition that causes at least one symptom. It is understood that at least humans, dogs, cats, and horses are within the scope of the meaning of the term. In some aspects, the patient is human. Generally, as used herein, the term "patient" means a human or an animal for which the compositions of the disclosure may be administered.
[0010] As used herein, the terms "treat", "treating", and "treatment" include inhibiting the pathological condition, disorder, or disease, e.g., arresting or reducing the development of the pathological condition, disorder, or disease or its clinical symptoms; or relieving the pathological condition, disorder, or disease, e.g., causing regression of the pathological condition, disorder, or disease or its clinical symptoms. These terms encompass also therapy and cure. Treatment means any manner in which the symptoms of a pathological condition, disorder, or disease are ameliorated or otherwise beneficially altered.
[0011] As used herein, the terms “benign prostatic hypertrophy (BPH)” and “benign prostatic hyperplasia” are used interchangeably and refer to the same disease in which the cells of the prostate tissue overgrow to a point where the prostate is beyond a normal size and causes pressure against the urethra and/or the bladder. This growth is benign and is not thought to be a precursor nor increase the risk of developing prostate cancer. BPH often results in urinary symptoms including impeded flow of urine and/or semen, frequent and/or urgent need to urinate, nocturia, inability to urinate, and/or incomplete voiding of the bladder.
[0012] As used herein, the term “mTOR complex 1 (mTORCl)” refers to a protein complex comprising mTOR, regulatory-associated protein of mTOR (RAPTOR), mammalian lethal with SEC 13 protein 8 (mLST8), proline-rich AKT substrate of 40 kDa (PRAS40) and DEP domain-containing protein 6 (DEPTOR) that has been described to function as a
nutrient/energy/redox sensor; regulator of cellular growth, proliferation, and motility; and controller of protein synthesis with roles in inflammation, autophagy and cell survival.
[0013] As used herein, the term “mTOR complex 2 (mTORC2)” refers to a protein complex comprising mTOR, mLST8, DEPTOR, rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-activated protein kinase interacting protein 1 (mSINl), and protein observed with rictor 1 and 2 (PROTORI/2) that has been described to function as an activator of insulin receptors and insulin-like growth hormone factor 1 receptors; and regulator of cell proliferation, cell migration and cytoskeletal remodeling with roles in signaling the production of cytokines, inflammation and cell survival.
[0014] As used herein, the term “mTOR inhibitor” refers to a composition that either directly or indirectly inhibits one or more functions of mTOR, mTORCl, mTORC2 and combinations thereof. Examples of suitable mTOR inhibitors include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit one or more mTOR protein complex functions.
[0015] As used herein, the term “thyroid hormone” refers to a composition that is either equivalent to, a derivative of, or affects the same functions as triiodothyronine (T3). Examples of suitable thyroid hormones include liothyronine, a T3 thyroid hormone composition.
[0016] Without being bound by theory, it is believed that the pathology of BPH involves a benign overgrowth of the prostate tissue to an extent that the prostate applies pressure to the urethra and/or the bladder and may cause one or more associated symptoms including impeded flow of urine, frequent and/or urgent need to urinate, nocturia, inability to urinate, and incomplete voiding of the bladder. The development of BPH is believed to be generally related to age with increased risk of experiencing the disease and its symptoms associated with family history, diabetes, heart diseases, erectile dysfunction and obesity. BPH can be a significant factor in the development of bladder, urinary tract and kidney diseases.
[0017] BPH is believed to be most common in men that are 80 years of age or older (about 50-90% or more), and less common at younger ages (about 33-50% by age 60 and relatively rare below age 40). In some cases, genetic factors have been shown to increase the risk of developing BPH up to six-fold. In severe cases of BPH, there is a complete blockage of urine flow that may require surgical intervention or catheter insertion to drain the bladder. In most cases of BPH, incomplete voiding of the bladder is believed to result in increased risk of
developing urinary tract infections; bladder stones; bladder infections, bladder irritation, hematuria; and damage to the muscular wall of the bladder. The kidneys may also be damaged by the inability to effectively urinate or from bladder or urinary tract infections that reach the kidneys. However, BPH is not believed to be a precursor to prostate cancer, nor is it believed to increase the risk of developing prostate cancer.
[0018] While several different treatments for BPH are available, including surgery, medications, and minimally invasive procedures to reduce the size of the prostate, some of these treatments may be contraindicated depending on the severity of the disease, other health conditions and side effects associated with the treatments. Mild cases of BPH may only call for active surveillance with recommendations for specific changes in diet and exercise. Whereas, moderate to severe cases of BPH generally involve treatment of some kind. Many options are currently available for treatment of BPH that have varying levels of success and potential side effects.
[0019] Medications are often prescribed to treat BPH prior to considering surgical options. Some of the pharmaceutical options include 5-alpha reductase inhibitors, alpha-adrenergic blockers, phosphodiesterase-5 inhibitors, or any combination thereof. Certain phytotherapies (herbal supplements, e.g. saw palmeho) have also been touted for their ability to treat BPH, but these therapies are not generally recommended by doctors and have been proven to be ineffective in several studies. 5-alpha reductase inhibitors have proven to have some beneficial effect in only about two-thirds of patients and are believed to act by blocking the production of the male hormone, dihydrotestosterone (DHT), which has been associated with activating prostate cell growth. However, 5-alpha reductase inhibitors are required to be continued indefinitely and the side effects can include impotence and gynecomastia as well as other sexual, physical, and psychological symptoms that may persist even after discontinuing therapy. Alpha-adrenergic blockers, which are believed to act by relaxing smooth muscle tissue in blood vessels and the prostate, have also proven to benefit only about two-thirds of patients with BPH. These agents also have side effects including orthostatic hypotension, fatigue, headaches, and ejaculatory dysfunction. Phosphodiesterase-5 inhibitors are also believed to act by relaxing smooth muscle of the prostate and bladder; however, despite exhibiting some beneficial effects of reducing urinary frequency and urgency, urinary flow was not shown to be significantly improved. Currently it is not possible to predict which patients will benefit from these medication therapies, and adverse effects can include sexual
dysfunction, physical changes including gynecomastia, muscle weakness and orthostatic hypotension, and psychological effects including depression, anxiety, and suicidal thoughts.
[0020] Minimally invasive procedures are often used after medicinal treatment has failed to be effective, and more invasive surgeries are considered when other methods have failed, or in the more severe cases of BPH. Minimally invasive procedures are not believed to reduce the risk that the patient will require subsequent surgery or additional medication, and these procedures may have side effects including hematuria, burning sensation when urinating, need to urinate more frequently, urinary tract infections, retrograde ejaculation, and erectile dysfunction. Examples of minimally invasive procedures include prostatic urethral lift, water vapor thermal therapy, transurethral microwave therapy, and catheterization. More invasive surgery in more severe cases of BPH include transurethral incision of the prostate, photoselective vaporization, transurethral resection of the prostate, holmium laser enucleation of prostate, thulium laser enucleation of the prostate, transurethral vaporization of the prostate and transurethral water-jet ablation. Possible side effects of more invasive therapies include urinary tract infections, urinary incontinence, dry orgasm, retrograde ejaculation, and erectile dysfunction.
[0021] Without being bound by theory, some studies have indicated that omega-6 fatty acids stimulate the growth of prostatic cells, while omega-3 fatty acids provide an inhibitory effect on prostate cell growth. Some of the changes believed to occur involve an increase in omega- 6 to omega-3 fatty acids that can interfere with the normal presentation and function of certain membrane-bound receptors including cell bound enzymes, calcium channels, sodium channels, potassium channels and other signaling proteins. As a result, the membrane bound proteins can become less responsive to stimuli including hormones, cell signaling proteins and cell signaling substances, which may in part be due to oxidative stress over time leading to changes in mTOR complex gene regulation and degradation of the omega-3 to omega-6 fatty acid ratio in cellular membranes.
[0022] Without being bound by theory, is it also believed that inflammation and improper immune response is associated with and can be contributing factors for predisposition to the development of BPH. It is believed that an inflammatory environment is created that is promoted by inflammatory cytokines and other chemicals, some of which are released from cell membranes as a result of an imbalance of the ratio of omega-3 to omega-6 fatty acids and some of which are released from senescent cells that accumulate over time associated with
aging. It is also believed that these pro-tumorigenic immune responses and inflammation are factors in inducing the growth of the prostate tissue.
[0023] Without being bound by theory, it is also believed that mTORCl and mTORC2 control multiple diffuse aspects of cellular metabolism, cellular integrity, cellular death, immune response and inflammation. It is believed that the mTORCl and mTORC2 activity is enhanced and driven upwards by cytokine release including those released as a result of higher than optimal ratios of omega-6 to omega-3 fatty acids in the cell membrane and that mTORCl and mTORC2 complex functions may be down regulated by the use of mTOR inhibitors. Examples of suitable mTOR inhibitors may include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit mTOR protein complexes.
[0024] It is further believed that part of the maintenance of the cell membrane may involve maintaining an optimal ratio of omega-3 to omega-6 fatty acids, which results in an anti inflammatory effect. It is believed that increasing the ratio of omega-3 to omega-6 fatty acids will lead to a decrease or an inhibition of cytokine production. Examples of omega-3 fatty acids include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are generally derived from diet. It is believed that EPA is superior to DHA for inhibition of inflammation and maintaining cell integrity. It is believed that omega-6 fatty acids (e.g. arachidonic acids) are precursors to the formation of cytokines. It is believed that omega-3 fatty acids may help to decrease cytokine production, for example, from the action of eicosanoid molecules. Accordingly, a decrease of omega-3 fatty acids, in relation to omega-6, may facilitate an inflammatory response caused by cytokines.
[0025] Without being bound by theory, it is believed that therapies including omega-3 fatty acids may downshift cellular signaling by decreasing cytokine formation. This may increase the maintenance of cellular adhesion and normal membrane anatomy with better sodium, potassium and calcium channel function and better response to stimuli from hormones, cell signaling proteins and other cell signaling substances such as nitric oxide. Therapies including omega-3 fatty acids may also facilitate the maintenance of membranes of mitochondria and other intracellular structures.
[0026] It is further believed that control over mTOR-associated protein complexes may also be of importance in the treatment of BPH. It is believed that mTOR-associated protein
complexes may respond to stimuli that alter cellular metabolism and growth. The mTOR- associated protein complexes may be involved in many diseases and almost all tissues of the body, including the prostate. It is believed that the dysregulation of mTORCl and mTORC2 may be an underlying cause of disease over one’s lifetime. It is also believed that overactivity of these protein complexes may lead to BPH.
[0027] Without being bound by theory, it is believed that biguanide antihyperglycemic agents act through inhibition of the mTORC2 complex to modulate cell functions including metabolism, proliferation, migration, and survival as well as reduce oxidative stress and inflammation. It is further believed that biguanide antihyperglycemic agents inhibit the mTORC2 complex by mechanisms including the reduction of the downstream effects of the AKT protein that is a component of the PBK/AKT/mTOR pathway. The PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle and is necessary to promote growth and proliferation over differentiation of adult stem cells. However, in BPH, this pathway is overactive, thus reducing apoptosis and allowing cell hypertrophy and proliferation. It is further believed that biguanide antihyperglycemic agents may be effective in treating BPH by reducing the downstream effect of the AKT protein in the PBK/AKT/mTOR pathway.
[0028] Without being bound by theory, it is believed that certain flavonoids act as senolytic agents by reducing mTOR complex activity, increasing the activity of sirtuins, and increasing the activity of AMP-activated protein kinase (AMPK). These actions are believed to play a role in cellular energy homeostasis and promotion of apoptosis in senescent cells that are resistant to signaling proteins and accumulate as we age during the aging process. It is further believed that the accumulation of senescent cells results from a weakened immune system related to aging, and these cells provide a source of chronic inflammation through the release of inflammatory chemicals and may lead to an increased risk of BPH. It is also believed that the mechanistic actions of certain flavonoids used in combination with a biguanide antihyperglycemic agent can exhibit synergistic effects for promoting apoptosis in senescent cells while promoting homeostasis in normal cells. It is further believed that when certain flavonoids are combined with certain galactomannans, the absorption of the certain flavonoids can be increased by as much as 25-fold.
[0029] Without being bound by theory, it is believed that compositions that include one or more mTOR inhibitors may be effective at treating BPH by decreasing inflammation,
enhancing cell membrane stability and function, and promoting apoptosis in senescent cells. It is also believed that compositions comprised of one or more mTOR inhibitors may be more effective if the composition is comprised of at least two or more mTOR inhibitors.
[0030] Thyroid hormones, including e.g. liothyronine (a T3 thyroid hormone), are believed to assist in controlling metabolism by utilizing oxygen and calories for conversion into energy in the mitochondria through the formation of ATP. Thyroid hormones are believed to be necessary for energy production in all organs, especially in muscle, brain, heart, and other tissues. Increased levels of thyroid hormones are believed to affect increased levels of cellular metabolism. Various tests are available to determine thyroid hormone levels, e.g. by measuring the amount of thyroid hormone levels in the blood. Thyroid hormones are believed to enhance cell survival and the metabolism of fats, proteins, and carbohydrates. It is further believed that treatment comprising one or more thyroid hormones in combination with a flavonoid, such as fisetin may act synergistically to increase metabolism and promote the senolytic effects of fisetin.
[0031] Thyroid hormones are believed to affect nearly every cell of the body through receptors in the nucleus of the cell. Thyroid hormones bind to DNA-binding nuclear hormone receptors, cause conformational changes in the receptors, and activate transcription of the thyroid hormone sensitive genes by either initiating expression or upregulation. Also, functions of the PI3K/AKT pathway are believed to include regulation of cell adhesion, cell cycle progression, cell survival and signaling. Precursors to the thyroid hormones, referred to as T4 or thyroxine, are believed to stimulate the PI3/AKT pathway in the cytoplasm, whereas T3 does not. T3 also has a shorter half-life than T4, so T3 is recommended for the treatment of hepatic steatosis over T4.
[0032] Without being bound by theory, it is believed that rapamycin is primarily an mTORl inhibitor at lower doses and for short treatment cycles, whereas high levels and very prolonged treatment cycles can also inhibit mTOR2 by blocking mTOR2 production by the cell. Rapamycin treatment is normally administered continuously either orally or intravenously, which frequently causes side effects of insulin resistance and hyperglycemia, and causes immune deficiency. Also, long-term treatment with rapamycin may decrease antigen processing and inhibit T-cell proliferation leading to suppression of the immune system. Rapamycin is also believed to decrease the phosphorylation of the ribosomal s6 kinase, S6K1, which is believed to result in active decreases in protein synthesis and cell mortality.
[0033] It is believed that treatment regimens that included rapamycin could be effective and safe if rapamycin is dosed at low-levels either intermittently or in conjunction with other mTOR inhibitors and/or additional medications that decrease or down regulate the PI3K-AKT pathway. It is further believed that using a biguanide antihyperglycemic agent, such as metformin, in these treatment regimens will allow for down regulation of both mTORl and mTOR2 safely without causing significant side effects of high-dose rapamycin. In addition to acting as an inhibitor of mTOR2, metformin also decreases glycolysis and is effective in controlling blood glucose levels. The addition of a flavonoid, such as fisetin, is believed to provide the added benefit of promoting apoptosis or cell death of senolytic cells effectuated at least partly through its inhibition of the mTOR pathway. The effects of fisetin may be further improved with the addition of a T3 thyroid hormone. It is believed that synergy of activity for inhibition of the PI3K-AKT pathway can be achieved with the combination of rapamycin, metformin, and fisetin while providing a low risk of side effects. The treatment regimens could further benefit from the addition of an omega-3 fatty acid derivative, which is believed to downregulate mTOR2, decrease cytokine formation, strengthen cell membranes and structures, and decrease phosphorylation of phosphatides. Additionally, the addition of a T3 thyroid hormone is believed to enhance the effectiveness of the therapy regimen. These combination therapies are believed to have minimal side effects, may be administered continuously over long periods of time, and result in an effective decrease in PI3K-AKT activity.
[0034] In various embodiments, the composition of the disclosure includes a composition for the treatment of BPH that includes an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. In various embodiments, suitable mTOR inhibitors may include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit mTOR protein complexes. In various embodiments, suitable thyroid hormones may include a T3 hormone, such as liothyronine.
[0035] Preferentially, at least one of the components of the composition will decrease pro- tumorigenic inflammation associated with cancer and primary cancer treatments.
[0036] Preferentially, at least one of the components of the composition will decrease the rate of normal cell death or will increase the life span of normal cells including those involved in immune response systems.
[0037] Preferentially, at least one of the components of the composition will enhance cellular membrane integrity and function and/or induce apoptosis in cancer and/or senescent cells. Preferentially, the compositions of the disclosure include a flavonoid, such as fisetin, at doses that are high enough to cause senescent cells to die and results in an overall decrease in inflammation in the patient.
[0038] Preferentially, the compositions of the disclosure include at least an effective amount of a biguanide antihyperglycemic agent in combination with an effective amount of an omega- 3 fatty acid derivative.
[0039] Preferentially, other than promoting euthyroid in patients, the compositions of the disclosure include a thyroid hormone concurrent with high doses of a flavonoid, such as fisetin.
[0040] In various embodiments, the composition may include an effective amount of an omega-3 fatty acid derivative. Suitable omega-3 fatty acid derivatives may include icosapent ethyl. In various embodiments, the composition of the disclosure may include an effective amount of at least about 0.5 g of icosapent ethyl, or between about 0.5 g to about 10.0 g, or 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7,
4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,
6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9,
9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10.0 g, or any range between any two of these amounts including about 0.5 g to about 10.0 g, or about 1.0 g to about 7.0 g, or about 2.0 g to about 8.0 g. In some preferred forms, the amount of icosapent ethyl is sufficient to maintain an optimum level of icosapent ethyl in the blood of a subject receiving an administration of the composition.
[0041] In various embodiments, the composition of the disclosure may include an effective amount of a biguanide antihyperglycemic agent. Suitable biguanide antihyperglycemic agents include metformin. In various embodiments, the composition may include an effective amount of at least about 50 mg of biguanide antihyperglycemic agent, or between about 50 mg to about 4000 mg, or 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, 1200, 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 1475, 1500, 1525, 1550, 1575, 1600, 1625, 1650, 1675,
1700, 1725, 1750, 1775, 1800, 1825, 1850, 1875, 1900, 1925, 1950, 1975, 2000, 2025, 2050,
2075, 2100, 2125, 2150, 2175, 2200, 2225, 2250, 2275, 2300, 2325, 2350, 2375, 2400, 2425,
2450, 2475, 2500, 2525, 2550, 2575, 2600, 2625, 2650, 2675, 2700, 2725, 2750, 2775, 2800,
2825, 2850, 2875, 2900, 2925, 2950, 2975, 3000, 3025, 3050, 3075, 3100, 3125, 3150, 3175,
3200, 3225, 3250, 3275, 3300, 3325, 3350, 3375, 3400, 3425, 3450, 3475, 3500, 3525, 3550,
3575, 3600, 3625, 3650, 3675, 3700, 3725, 3750, 3775, 3800, 3825, 3850, 3875, 3900, 3925,
3950, 3975, or 4000 mg or any range between any two of these amounts including about 250 mg to about 4000 mg, about 250 mg to about 500 mg, about 250 mg to about 750 mg, 250 mg to about 1000 mg, about 250 mg to about 1250 mg, about 250 mg to about 1500 mg, or between about 500 mg to about 3000 mg.
[0042] In various embodiments, the composition may include an effective amount of a flavonoid. Suitable flavonoid agents include fisetin and fisetin derivatives. In various embodiments, the composition may include an effective amount of at least about 10 mg/kg of patient body weight of a flavonoid, or between about 10 mg/kg to about 100 mg/kg of patient body weight, or 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg/kg of patient body weight or any range between any two of these amounts including about 10 mg/kg to about 20 mg/kg, about 15 mg/kg to about 25 mg/kg, about 20 mg/kg to about 30 mg/kg, about 25 mg/kg to about 50 mg/kg, or about 20 mg/kg to about 100 mg/kg. In some preferred forms, the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition. In some embodiments, such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid.
[0043] In various embodiments, the composition may include an effective amount of a flavonoid. Suitable flavonoid agents include fisetin and fisetin derivatives. In various embodiments, the composition may include an effective amount at least about 50 mg of a flavonoid, or between about 50 mg to about 750 mg, or 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190,
195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285,
290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380,
385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475,
480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570,
575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665,
670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, or 750 mg or any range between any two of these amounts including about 50 mg to about 500 mg, about 100 mg to about 750 mg, about 250 mg to about 500 mg, about 250 mg to about 750 mg, about 500 mg to about 750 mg, or about 100 mg to about 500 mg. In some preferred forms, the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition. In some embodiments, such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid.
[0044] In various embodiments, the compositions may include an effective amount of a macrolide. Suitable macrolides include rapamycin. In various embodiments, the compositions may include an effective amount of a macrolide of at least about 0.1 mg of a macrolide, or between about 0.1 mg to about 10 mg, or 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2,
1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3,
3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4,
5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5,
7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6,
9.7, 9.8, 9.9, or 10.0 mg or any range between any two of these amounts including about 2.0 mg to about 6.0 mg, about 1.0 mg to about 10.0 mg, about 2.0 mg to about 4.0 mg, about 2.5 mg to about 5.0 mg, about 2.5 mg to about 7.5 mg, or about 1.0 mg to about 5.0 mg of a macrolide. In some preferred forms, the amount of rapamycin is administered as a loading dose followed by a lower daily dose. In some preferred forms, the amount of rapamycin is sufficient to maintain an optimum level of rapamycin in the blood of a subject receiving an administration of the composition; such optimum level may be determined as a preferred optimum trough level as measured in nanograms per ml of blood. In some preferred forms, the administration of rapamycin is provided intermittently at low levels.
[0045] In various embodiments, the compositions may include an effective amount of a thyroid hormone. Suitable thyroid hormones include the T3 liothyronine. In various embodiments, the compositions of the disclosure may include an effective amount of at least about 1 pg of liothyronine, or between about 1 pg to about 250 pg, or 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,
60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,
127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145,
146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,
165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183,
184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,
203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221,
222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240,
241, 242, 243, 244, 245, 246, 247, 248, 249, 250 pg, or any range between any two of these amounts including about 5 pg to about 150 pg, or about 10 pg to about 100 pg, or about 10 pg to about 25 pg, or about 25 pg to about 150 pg, or about 25 pg to about 250 pg. In some preferred forms, the amount of liothyronine is sufficient to maintain an optimum level of liothyronine in the blood of a subject receiving an administration of the composition.
[0046] In various embodiments, the compositions may include an effective amount of a combination of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones. In various embodiments, the compositions may include an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a flavonoid. In various embodiments, the compositions may include an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a high dose of a flavonoid, which is associated with a senolytic effect.
[0047] In various embodiments, the composition of the disclosure may further contain additional pharmaceutically acceptable carriers. The pharmaceutical compositions may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulation, solution or suspension, in a form suitable for parenteral injection as a sterile solution, suspension, or in a form of an emulsion for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical compositions may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical compositions may include conventional pharmaceutical carriers or excipients. In addition, the compositions may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
[0048] In various embodiments, the composition may be administered to a patient through any suitable route of administration effective in delivering an amount of active agent or active agents to a patient. Suitable routes of administration include oral, parenteral, enteral, and rectal or the like.
[0049] In some forms, the composition will comprise each of the ingredients in a single administration form, such as a pill, tablet, capsule, oral solution, injection solution, infusion solution, or any of the forms described herein. In other forms, the composition will comprise a kit comprising each of the individual ingredients, together with instructions for administering each ingredient. In some forms of the kit, certain ingredients will already be combined such that two, three, or more of the components or ingredients of the composition are in a single administration form as described herein.
[0050] Various embodiments of the disclosure further relate to methods for the treatment of BPH comprising the administration of a composition of an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. In various embodiments, suitable mTOR inhibitors may include omega-3 fatty acid derivatives, biguanide antihyperglycemic agents, flavonoids, macrolides, and other agents that effectively inhibit mTOR protein complexes. In various embodiments, suitable thyroid hormones may include a T3 hormone, such as liothyronine.
[0051] In various embodiments, the methods may include administering an effective amount of an omega-3 fatty acid derivative. Suitable omega-3 fatty acid derivatives may include icosapent ethyl. In various embodiments, the methods may include administering an effective amount of at least about 0.5 g of icosapent ethyl, or between about 0.5 g to about 10.0 g, or 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6,
2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7,
4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,
6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9,
9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10.0 g, or any range between any two of these amounts including about 0.5 g to about 10.0 g, or about 1.0 g to about 7.0 g, or about 2.0 g to about 8.0 g once, twice, or three or more times daily. In some preferred forms, the amount of icosapent ethyl is sufficient to maintain an optimum level of icosapent ethyl in the blood of a subject receiving an administration of the composition.
[0052] In various embodiments, the method may include administering an effective amount of a biguanide antihyperglycemic agent. Suitable biguanide antihyperglycemic agents include metformin. In various embodiments, the methods may include administering an effective amount of at least about 50 mg of biguanide antihyperglycemic agent, or between about 50 mg to about 4000 mg, or 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, 1200, 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 1475, 1500, 1525, 1550, 1575, 1600, 1625, 1650, 1675, 1700, 1725, 1750, 1775, 1800, 1825, 1850, 1875, 1900, 1925, 1950, 1975, 2000, 2025, 2050, 2075, 2100, 2125, 2150, 2175, 2200, 2225, 2250, 2275, 2300, 2325, 2350, 2375, 2400, 2425, 2450, 2475, 2500, 2525, 2550, 2575, 2600, 2625, 2650, 2675, 2700, 2725, 2750, 2775, 2800, 2825, 2850, 2875, 2900, 2925, 2950, 2975, 3000, 3025, 3050, 3075, 3100, 3125, 3150, 3175, 3200, 3225, 3250, 3275, 3300, 3325, 3350, 3375, 3400, 3425, 3450, 3475, 3500, 3525, 3550, 3575, 3600, 3625, 3650, 3675, 3700, 3725, 3750, 3775, 3800, 3825, 3850, 3875, 3900, 3925, 3950, 3975, or 4000 mg or any range between any two of these amounts including about 250 mg to about 4000 mg, about 250 mg to about 500 mg, about 250 mg to about 750 mg, 250 mg to about 1000 mg, about 250 mg to about 1250 mg, about 250 mg to about 1500 mg, or between about 500 mg to about 3000 mg once, twice, or three or more times daily.
[0053] In various embodiments, the method may include administering an effective amount of a flavonoid. Suitable flavonoid agents include fisetin and fisetin derivatives. In various embodiments, the methods may include administering an effective amount of at least about 10 mg/kg of patient body weight of a flavonoid, or between about 10 mg/kg to about 100 mg/kg of patient body weight, or 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg/kg of patient body weight or any range between any two of these amounts including about 10 mg/kg to about 20 mg/kg, about 15 mg/kg to about 25 mg/kg, about 20 mg/kg to about 30 mg/kg, about 25 mg/kg to about 50 mg/kg, or about 20 mg/kg to about 100 mg/kg once, twice, or three or more times daily, weekly, monthly, trimonthly or intermittently with periods between administration when no flavonoid is administered. In some preferred methods, the flavonoid may be administered each day for two days on a weekly, monthly or trimonthly basis. In some preferred methods, the flavonoid may be administered each day for two days twice monthly for six months followed by administration one day per month. In some preferred methods, the flavonoid may be administered once every two weeks on a monthly basis for six to twelve months followed by administration once every month. In some preferred methods,
the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition; such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid. In various embodiments, a higher dose of fisetin may be associated with a senolytic effect. In various embodiments, a lower dose of fisetin may be associated with an antioxidant effect.
[0054] In various embodiments, the method may include administering an effective amount of a flavonoid that is administered on a daily basis. Suitable flavonoid agents include fisetin and fisetin derivatives. In various embodiments, the methods may include administering an effective amount of at least about 50 mg of a flavonoid, or between about 50 mg to about 750 mg, or 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240,
245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335,
340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430,
435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525,
530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620,
625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715,
720, 725, 730, 735, 740, 745, or 750 mg or any range between any two of these amounts including about 50 mg to about 500 mg, about 100 mg to about 750 mg, about 250 mg to about 500 mg, about 250 mg to about 750 mg, about 500 mg to about 750 mg, or about 100 mg to about 500 mg once, twice, or three or more times daily. In some preferred methods, the flavonoid may be administered each day for two days on a weekly, monthly or trimonthly basis. In some preferred methods, the flavonoid may be administered each day for two days twice monthly for six months followed by administration one day per month. In some preferred methods, the flavonoid may be administered once every two weeks on a monthly basis for six to twelve months followed by administration once every month. In some preferred methods, the amount of fisetin is sufficient to maintain an optimum level of fisetin in the blood of a subject receiving an administration of the composition; such optimum level may be achieved by combining the fisetin with a galactomannan to enhance the absorption of the flavonoid. In various embodiments, a higher dose of fisetin may be associated with a senolytic effect. In various embodiments, a lower dose of fisetin may be associated with an antioxidant effect.
[0055] In various embodiments, the methods may include administering an effective amount of a macrolide. Suitable macrolides include rapamycin. In various embodiments, the methods
may include administering an effective amount of a macrolide of at least about 0.1 mg of a macrolide, or between about 0.1 mg to about 10 mg, or 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0,
3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1,
5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2,
7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3,
9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10.0 mg or any range between any two of these amounts including about 2.0 mg to about 6.0 mg, about 1.0 mg to about 10.0 mg, about 2.0 mg to about 4.0 mg, about 2.5 mg to about 5.0 mg, about 2.5 mg to about 7.5 mg, or about 1.0 mg to about 5.0 mg of a macrolide. In some preferred forms, the amount of rapamycin is administered as a loading dose followed by a lower daily dose. In some preferred forms, the amount of rapamycin is sufficient to maintain an optimum level of rapamycin in the blood of a subject receiving an administration of the composition; such optimum level may be determined as a preferred optimum trough level as measured in nanograms per ml of blood. In some preferred forms, the administration of rapamycin is provided intermittently at low levels.
[0056] In various embodiments, the methods may include administering an effective amount of an omega-3 fatty acid derivative in a dosing regimen with an effective amount of a biguanide antihyperglycemic agent.
[0057] In various embodiments, the methods may include administering an effective amount of an omega-3 fatty acid derivative in a dosing regimen with an effective amount of a flavonoid.
[0058] In various embodiments, the methods may include administering an effective amount of a biguanide antihyperglycemic agent in a dosing regimen with an effective amount of a flavonoid.
[0059] In various embodiments, the methods may include administering an effective amount of an omega-3 fatty acid derivative in a dosing regimen with an effective amount of a biguanide antihyperglycemic agent and an effective amount of a flavonoid.
[0060] In various embodiments, the methods may include administering an effective amount of a thyroid hormone. Suitable thyroid hormones include the T3 liothyronine. In various embodiments, the methods of the disclosure may include administering an effective amount of at least about 1 pg of liothyronine, or between about 1 pg to about 250 pg, or 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125,
126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,
145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163,
164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182,
183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,
202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220,
221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239,
240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 mg, or any range between any two of these amounts including about 5 pg to about 150 pg, or about 10 pg to about 100 pg, or about 10 pg to about 25 pg, or about 25 pg to about 150 pg, or about 25 pg to about 250 pg either weekly, bimonthly, or monthly; however, thyroid hormones should not be given daily and administration should not exceed three days per week. In some preferred methods, the administration of thyroid hormones is dependent upon the clinical response and tolerance of the patient and may continue long-term including many years. In some preferred methods, the amount of liothyronine administered is sufficient to maintain an optimum level of liothyronine in the blood of a subject receiving an administration of the composition.
[0061] In various embodiments, the methods may include diagnosing thyroid functions in each patient prior to administration of an effective amount of a thyroid hormone. In various embodiments, the methods for patients requiring thyroid hormone replacement in order to establish normal thyroid functions may preferentially be administered a T3 thyroid hormone. In various embodiments, patients with normal thyroid functions may be administered a low dose of a T3 thyroid hormone (e.g. 5 to 10 pg of liothyronine) combined with a high dose of a flavonoid. In various embodiments, the methods may include administering a combination of a low dose of a T3 thyroid hormone and a high dose of a flavonoid that effectively elicits a synergistic effect of increasing fat metabolism and promoting cellular senescence. In various embodiments, other than promoting euthyroid in patients, the methods include administering a thyroid hormone concurrent with high doses of a flavonoid, such as fisetin.
[0062] In various embodiments, the methods may include administering an effective amount of a combination of thyroid hormones. Suitable thyroid hormones that may be included in the
combination include the T3 liothyronine. In various embodiments, the methods may include administering an effective amount of a combination of one or more thyroid hormones with an effective amount of a flavonoid. In various embodiments, the methods may include administering an effective amount of one or more thyroid hormones and an effective amount of a high dose of a flavonoid, which is associated with a senolytic effect unless the patient is hypo thyroid on the days of the week the thyroid hormone is administered. In various embodiments, the methods may include administering a combination of an effective amount of one or more thyroid hormones with either an effective amount of a flavonoid or a high dose of a flavonoid, wherein only some of the compositions that include an effective amount of a flavonoid also include an effective amount of one or more thyroid hormones. For example, an effective amount of one or more thyroid hormones may be included only in one of two weekly compositions administered that includes an effective amount of a flavonoid or a high dose of a flavonoid, which composition could be either the first or second weekly composition administered that includes a flavonoid or high dose flavonoid.
[0063] In various embodiments, the methods may include administering an effective amount of a combination of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones. In various embodiments, the methods may include administering an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a flavonoid. In various embodiments, the methods may include administering an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and an effective amount of a high dose of a flavonoid, which is associated with a senolytic effect. In various embodiments, the methods may include administering a combination of an effective amount of one or more mTOR inhibitors with an effective amount of one or more thyroid hormones and either an effective amount of a flavonoid or a high dose of a flavonoid, wherein only some of the compositions that include an effective amount of a flavonoid also include an effective amount of one or more thyroid hormones. For example, an effective amount of one or more thyroid hormones may be included only in one of two weekly compositions administered that includes an effective amount of a flavonoid or a high dose of a flavonoid, which composition could be either the first or second weekly composition administered that includes a flavonoid or high dose flavonoid. In various embodiments, the one or more thyroid hormones should be administered for short durations (for example, two days a week, bimonthly, or monthly) during any periods of a dosing regimen that include a high dose of a flavonoid.
[0064] In some preferred forms, the methods include administering a macrolide, such as rapamycin; in combination with a biguanide antihyperglycemic agent, such as metformin; in combination with an omega-3 fatty acid derivative, such as icosapent ethyl; in combination with a flavonoid, such as fisetin; and in combination with a T3 thyroid hormone, such as liothyronine. In some preferred forms, the methods include administering a macrolide, such as rapamycin, dosed weekly to achieve blood levels below specified levels measured at specified times following administration; in combination with a biguanide antihyperglycemic agent, such as metformin, dosed twice daily; in combination with an omega-3 fatty acid derivative, such as icosapent ethyl, dosed twice daily; in combination with a flavonoid, such as fisetin, dosed daily; in combination with a T3 thyroid hormone, such as liothyronine, dosed either for two days in a row per week or dosed on separated days for no more than 3 days per week. In some preferred forms, the methods include administering a macrolide, such as rapamycin, dosed weekly to achieve blood levels below about 12 nanograms per ml of blood measured at about 60 hours plus or minus 3 hours following administration; in combination with a biguanide antihyperglycemic agent, such as metformin, dosed twice daily at about 500 mg to about 2000 mg; in combination with an omega-3 fatty acid derivative, such as icosapent ethyl, dosed twice daily at about 2.0 g to about 4.0 g; in combination with a flavonoid, such as fisetin, dosed daily at about 20.0 mg/kg patient body weight (which dose may be achieved by starting at a daily dose of about 200 mg and stepping up to the daily dose of about 20.0 mg/kg); in combination with a T3 thyroid hormone, such as liothyronine, dosed either for two days in a row per week or dosed on separated days for no more than 3 days per week at about 5.0 pg to about 10.0 pg. In some preferred forms, the methods include administering a composition that does not include a macrolide, such as rapamycin, when it is not clinically necessary. In some preferred forms, the macrolide is administered intermittently, as directed by a physician. In some forms, the macrolide is administered daily or twice daily as set forth above for a period of 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35,
40, 45, 50, 55, 60, or more days in a row wherein it is then not administered for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, or more days in a row. Once the period of non-administration is complete, the macrolide is again administered as set forth herein before another period of non administration. This process can be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, or more times.
[0065] In various embodiments, the methods may include administering the effective amount of the compositions of the disclosure that may further contain at least one additional pharmaceutically acceptable carriers, excipients, other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
[0066] In various embodiments, the methods may include administering the effective amount of the compositions to a patient through any suitable route of administration effective in delivering an amount of active agent or active agents to a patient. Suitable routes of administration include oral, intravascular, intramuscular, subcutaneous, parenteral, enteral, and rectal or the like.
[0067] In various embodiments, the methods may include administering the effective amount of the compositions comprised of each of the ingredient in a single administration form, such as a pill, tablet, capsule, oral solution, injection solution, infusion solution, or any of the forms described herein. In various embodiments, the methods may include administering the effective amount of the compositions from a kit comprising each of the individual ingredients, together with instructions for administering each ingredient. In some forms of the kit, certain ingredients will already be combined such that one, two, three, four, or more of the components or ingredients of the composition are in a single administration form as described herein.
[0068] Example
[0069] Treatment with Icosapent Ethyl, Metformin, and Fisetin
[0070] Normal total PSA levels are considered to be at or below 4.0 ng/ml. A patient experiencing elevated total PSA levels of about 5.3 ng/ml on average during about a 4 year period was treated with the following regimen: Vescepa® (icosapent ethyl) dosed at 2 grams twice daily, metformin dosed twice daily at 750 mg each morning and 500 mg each evening, and fisetin dosed two times weekly at 1,400 mg on Monday and Tuesday of each week. The treatment regimen was conducted for 1 month at which time total PSA levels were tested and found to return to a normal level of 3.89 ng/ml, representing about a 27% decrease in total PSA level.
[0071] This writen description uses examples to disclose the subj ect mater herein, including the best mode, and also to enable any person skilled in the art to practice the subject mater disclosed herein, including making and using any devices or systems and performing any incorporated methods. The patentable scope of the disclosure is defined by the claims, and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal languages of the claims.
Claims
1. A pharmaceutical composition for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors.
2. The pharmaceutical composition of claim 1 , wherein the one or more mTOR inhibitors is selected from the group consisting of: an omega-3 fatty acid derivative, a biguanide antihyperglycemic agent, a flavonoid, a macrolide, and any combination thereof.
3. The pharmaceutical composition of claim 2, wherein the omega-3 fatty acid derivative is icosapent ethyl.
4. The pharmaceutical composition of claim 2, wherein the biguanide antihyperglycemic agent is metformin.
5. The pharmaceutical composition of claim 2, wherein the flavonoid is selected from the group consisting of fisetin and fisetin derivatives.
6. The pharmaceutical composition of claim 2, wherein the macrolide is selected from the group consisting of rapamycin and rapamycin derivatives.
7. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition further comprises an effective amount of one or more thyroid hormones.
8. The pharmaceutical composition of claim 7, wherein the one or more thyroid hormones include liothyronine.
9. The pharmaceutical composition of claim 8, wherein the flavonoid is selected from the group consisting of fisetin and fisetin derivatives.
10. The pharmaceutical composition of claim 9, wherein the omega-3 fatty acid derivative is icosapent ethyl, the biguanide antihyperglycemic agent is metformin, and the macrolide is rapamycin.
11. A method for the administration of a pharmaceutical composition for the treatment of benign prostatic hypertrophy comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors.
12. The method of claim 11 , wherein the one or more mTOR inhibitors is selected from the group consisting of: an omega-3 fatty acid derivative, a biguanide antihyperglycemic agent, a flavonoid, a macrolide, and combinations thereof.
13. The method of claim 12, wherein the omega-3 fatty acid derivative is icosapent ethyl.
14. The method of claim 12, wherein the biguanide antihyperglycemic agent is metformin.
15. The method of claim 12, wherein the flavonoid is selected from the group consisting of fisetin and fisetin derivatives.
16. The method of claim 12, wherein the macrolide is selected from the group consisting of rapamycin and rapamycin derivatives.
17. The method of claim 12, wherein the pharmaceutical composition further comprises an effective amount of one or more thyroid hormones.
18. The method of claim 17, wherein the one or more thyroid hormones include liothyronine.
19. The method of claim 18, wherein the flavonoid is selected from the group consisting of fisetin and fisetin derivatives.
20. The method of claim 19, wherein the omega-3 fatty acid derivative is icosapent ethyl, the biguanide antihyperglycemic agent is metformin, and the macrolide is rapamycin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163175600P | 2021-04-16 | 2021-04-16 | |
US63/175,600 | 2021-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022221886A1 true WO2022221886A1 (en) | 2022-10-20 |
Family
ID=83641041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/071781 WO2022221886A1 (en) | 2021-04-16 | 2022-04-18 | Compositions for the treatment of benign prostatic hypertrophy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022221886A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
US20110201664A1 (en) * | 2005-10-14 | 2011-08-18 | Zweig Jack I | Methods and Compositions for Treatment of Prostate Intraepithelial Neoplasia |
WO2019104065A1 (en) * | 2017-11-22 | 2019-05-31 | Turrinii Pharmaceutical, Llc | Anti-aging methods and compositions |
-
2022
- 2022-04-18 WO PCT/US2022/071781 patent/WO2022221886A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110201664A1 (en) * | 2005-10-14 | 2011-08-18 | Zweig Jack I | Methods and Compositions for Treatment of Prostate Intraepithelial Neoplasia |
US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
WO2019104065A1 (en) * | 2017-11-22 | 2019-05-31 | Turrinii Pharmaceutical, Llc | Anti-aging methods and compositions |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "Animal Data Shows Fisetin to be a Surprisingly Effective Senolytic ", FIGHT AGING!, 3 October 2018 (2018-10-03), XP093000218, Retrieved from the Internet <URL:https://www.fightaging.org/archives/2018/10/animal-data-shows-fisetin-to-be-a-surprisingly-effective-senolytic/#:-:text=Animal%20Data%20Shows%20Fisetin%20to%20be%20a%20Surprisingly%20Effective%20Senolytic,-Permaiink%20Read%20331&text=lt%20is%20exciting%20to%20see,as%20first%20generation%20rejuvenation%20therapies> [retrieved on 20221121] * |
SHIROOIE: "Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?", PHARMACOL RESEARCH. WEB, 7 July 2018 (2018-07-07), pages 37 - 48, XP085470172, Retrieved from the Internet <URL:https://pubmed.ncbi.nlm.nih.gov/29990625> [retrieved on 20220706], DOI: 10.1016/j.phrs.2018.07.004 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014236004B2 (en) | Compositions and methods for producing elevated and sustained ketosis | |
Pei et al. | Effect of quercetin on nonshivering thermogenesis of brown adipose tissue in high-fat diet-induced obese mice | |
AU2020200726B2 (en) | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues | |
Davis et al. | High-intensity interval training and calorie restriction promote remodeling of glucose and lipid metabolism in diet-induced obesity | |
TW201615221A (en) | The new indication of the anti-inflammatory drugs | |
US10172839B2 (en) | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues | |
Nardi et al. | Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery | |
Kwapis et al. | The role of the medial prefrontal cortex in trace fear extinction | |
Alexander | Nutrition and infection: New perspectives for an old problem | |
US5276018A (en) | Composition comprising amino acids and methods for decreasing muscle breakdown | |
ES2712944T3 (en) | Annatto extract compositions, including geranylgeraniols for use in reducing the level of triglycerides in the blood | |
Perea | Parenteral nutrition | |
Lu et al. | Aqueous extract of Paeoniae Radix Rubra prevents deep vein thrombosis by ameliorating inflammation through inhibiting GSK3β activity | |
Fabius et al. | Evidence‐based therapy for atypical myopathy in horses | |
JP2018516934A (en) | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for reducing fat mass | |
Hyun et al. | Reversibility of sarcopenia by Ishige okamurae and its active derivative diphloroethohydroxycarmalol in female aging mice | |
Kramer et al. | Modulation of temporomandibular joint nociception and inflammation in male rats after administering a physiological concentration of 17β‐oestradiol | |
US20220409567A1 (en) | Adjuvant and complementary therapies for the treatment of cancer | |
US20210401812A1 (en) | Compositions for the prevention and treatment of metabolic syndrome | |
WO2022221886A1 (en) | Compositions for the treatment of benign prostatic hypertrophy | |
US20210379027A1 (en) | Compositions for the treatment of hepatic steatosis | |
US20220304986A1 (en) | Compositions and methods for treating acquired brain injury and post-traumatic stress disorder | |
WO2022094251A1 (en) | Compositions and methods for treating neurological disorders | |
Ferini-Strambi et al. | Treatment of restless legs syndrome | |
KR20200088765A (en) | Treatment for interstitial cystitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22789141 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22789141 Country of ref document: EP Kind code of ref document: A1 |